purpose present treatment outcomes hypofractionated proton beam therapy stage lung cancer nsclc methods materials patients stage nsclc NUMBER stage ia NUMBER stage ib underwent hypofractionated proton beam therapy time irradiation patient age ranged NUMBER NUMBER years median NUMBER years patients medically inoperable comorbidities NUMBER patients refused surgical resection histology squamous cell carcinoma NUMBER patients adenocarcinoma NUMBER large cell carcinoma NUMBER tumor size ranged NUMBER NUMBER mm median NUMBER mm maximum diameter NUMBER patients received proton beam irradiation total doses NUMBER gy NUMBER gy NUMBER fractions respectively primary tumor sites results NUMBER patients NUMBER died cancer NUMBER died pneumonia median period NUMBER months overall survival rates NUMBER NUMBER respectively irradiated tumors controlled period patients showed recurrences months treatment including local progression new lung lesions outside irradiated volume NUMBER NUMBER patients respectively local rates NUMBER NUMBER NUMBER years respectively toxicity grade NUMBER observed conclusions hypofractionated proton beam therapy feasible effective stage nsclc proton beams contribute enhanced efficacy lower toxicity treatment patients stage nsclc high dose non small cell high dose follow NUMBER year cause specific follow NUMBER NUMBER progression free disease free therapy related high dose